- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
- Interventions
- enfortumab vedotin (EV), pembrolizumab, cisplatin, carboplatin, gemcitabine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 83
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 75 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- Erdafitinib Intravesical Delivery System
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo
- Drug · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 907 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer, Urogenital Neoplasms, Urologic Neoplasms, Urologic Cancer, Malignant Tumor of the Urinary Bladder, Cancer of the Bladder
- Interventions
- NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care, NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
- Drug · Other
- Lead sponsor
- NanOlogy, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), Cisplatin, Fluorouracil (5-FU), Mitomycin C (MMC), Gemcitabine, Placebo to Pembrolizumab
- Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 24
- States / cities
- Washington D.C., District of Columbia • Bay Pines, Florida • Orlando, Florida + 20 more
- Conditions
- Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
- Interventions
- Sacituzumab govitecan, Adaptive Radiotherapy
- Drug · Radiation
- Lead sponsor
- Shilpa Gupta, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Bladder Cancer
- Interventions
- Tissue Biopsy, Magnetic Resonance Imaging (MRI)
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- therapeutic conventional surgery, whole breast irradiation
- Procedure · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 350
- States / cities
- Hot Springs, Arkansas • Dublin, California • Emeryville, California + 216 more
- Conditions
- Breast Cancer
- Interventions
- BIBF 1120, Phone Call
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
- Interventions
- This is a non-interventional, observational, prospective study.
- Other
- Lead sponsor
- Bladder Cancer Advocacy Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer
- Interventions
- Avelumab
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin
- Biological · Procedure · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 808 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma
- Interventions
- Enfortumab vedotin, Pembrolizumab
- Drug
- Lead sponsor
- Matthew Galsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Duarte, California • Indianapolis, Indiana • New York, New York + 1 more
- Conditions
- Muscle-invasive Bladder Cancer
- Interventions
- Atezolizumab, Placebo, Signatera
- Drug · Other · Device
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 761 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Rockledge, Florida • Cleveland, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
- Interventions
- Intravenous fluids, ERAS
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Entinostat, Procedure/Surgery
- Drug · Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Urinary Bladder Cancer, Muscle-invasive
- Interventions
- Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin
- Drug · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 39
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Fullerton, California + 31 more
- Conditions
- Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
- Interventions
- Gemzar, Cisplatin, Adrucil, Mitomycin, Radical Cystectomy
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
- Interventions
- Eribulin Mesylate, Grapiprant
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 8
- States / cities
- Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more
- Conditions
- Bladder Cancer, Muscle Invasive Bladder Cancer
- Interventions
- Avelumab, Radiation
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Urothelial Carcinoma, Muscle-invasive Bladder Cancer
- Interventions
- Sacituzumab Govitecan (SG), Nivolumab
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Durvalumab, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,063 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- APL-1202 in combination with tislelizumab, Tislelizumab alone
- Drug
- Lead sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York